CD24 and cancer: These trials were phase I/II studies to determine the safety and tolerability of the CD24 extracellular domain-IgG1 Fc domain recombinant fusion protein, CD24Fc (CD24Fc), in patients with advanced solid tumors who developed debilitating immune-related adverse events (irAEs) from immune checkpoint inhibitors (ICIs) and to determine if CD24Fc shortens the recovery time of irAEs and increases the recovery rate of irAEs in cancer patients with grade 2 or 3 irAEs.